Exclusive Perpetual Licenses - Apollon Patents & IP

Global Hemp Group is acquiring the exclusive perpetual license for North America (the United States, Canada and Mexico) to certain Intellectual Property and proprietary technology from Apollon Formularies, Plc, including, but not limited to, four key patents as described below including any continuations, divisionals, and continuations-in-part, along with any and all associated pre-clinical and clinical data relating to the patents and proprietary technology (the “IP”).

Apollon Formularies Plc is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform.

GHG will look to begin monetizing the IP being licensed from Apollon by sub-licensing it in North America. To assist the Company in achieving this goal of creating an ongoing revenue stream, GHG has engaged Dr. Stephen D. Barnhill, creator of the IP and Chairman & CEO of Apollon, as Special Medical Advisor to the Company. To date, Apollon as a company listed on the Aquis Exchange in the UK, were unable to enter the North American market due to jurisdictional constraints. The same is not true for a Canadian company trading on the CSE.

Intellectual Property - Patent Information and Independent Test Data Being Licensed GHG will acquire the exclusive perpetual license to the following patents (including any continuations, divisional and continuations-in-part) and any associated pre-clinical and clinical data relating to the patents. The patents are registered under the International Patent System (PCT) and are also registered in Jamaica. This exclusive perpetual license will cover Canada, the United States and Mexico, for the four patents below and all associated supporting data:

· Compositions and Methods for Treatment of Cancers;

· Compositions and Methods for Treatment of Inflammation;

· Methods for Treatment of Human Cancers Using Cannabis Compositions;

· Methods for Treatment of Human Cancers Using Mushroom Compositions;

· BIOENSIS Pre-clinical Data reflecting independent 3D cell culture testing of cannabis and mushroom formulations included in the patent applications.

These patents include claims to the treatments of cancers and inflammatory conditions using natural biologics including compounds in medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds that have been shown in independent, third-party pre-clinical 3D cell culture testing to kill cancer cells via direct cytotoxicity and immune stimulated cytotoxicity with great success and high efficacy. Under the Exclusive License Agreement, GHG will have the right to sublicense this intellectual property to legally licensed producers in the United States (state by state where medicinal cannabis is legal), Canada and Mexico, which allows the opportunity to generate significant near-term sublicensing revenue in these three countries.